News and Press Releases

Valo Therapeutics recruits Petri Priha as Vice President CMC

Petri Priha

Petri Priha, VP of CMC, has over 20 years’ experience in expert and management positions in vaccine, biopharmaceutical protein, and oncolytic adenovirus process development and GMP manufacturing. Prior to joining Valo Therapeutics in January 2017, Petri served as VP of CMC at Targovax, and before that as Director of Process Development and Quality Assurance at Oncos Therapeutics. During his 5 years at Oncos, he was responsible for the CMC development of an oncolytic adenovirus cancer immunotherapy platform. Petri also served at Ipsat Therapies for 9 years as Director of Production and Quality of prophylactic biopharmaceutical proteins targeted to prevent antibiotic-associated secondary infections. Prior to that, he worked at the National Institute for Health and Welfare, where he was responsible for bacterial vaccine manufacturing. Petri is a chemical engineer (Lic. Sc. Tech.) from Helsinki University of Technology.